An effective anti-tumor immune response can control and eradicate tumors, but tumors employ diverse strategies of establishing immune-tolerance or avoid immune-recognition.  The profile of immune cells in the tumor microenvironment, including the presence of activated T-cells predict positive outcomes across many cancers.  Natural nucleotides and nucleoside-derivative molecules play immunomodulatory roles in the tumor.  Riboscience is developing a novel oral treatment to improve the anti-cancer immune response and break immune tolerance across many different types of cancers.  

The small molecule immunotherapy by Riboscience has potential to improve treatment responses in the main causes of cancer death: Lung cancer, Colorectal Cancer, Pancreatic cancer, Breast cancer, Liver cancer.  

Riboscience enabled structure-guided lead generation and optimization for a novel protein target that is upregulated and essential for tumor growth in many cancer types.  This new mechanism of action prevents tumor growth and induces cancer cell apoptosis.    

Currently available treatment options for HBV can rarely suppress infectious virus production in the liver and consequently have low cure rates (<5%).  A more complete suppression of virus replication will support key strategies to cure HBV infection in a majority of people with chronic hepatitis B.  

Riboscience is developing a small molecule treatment of HBV infection with the potential to fully suppress HBV replication in the liver, increase cure rates and reduce the incidence of HBV-associated severe liver disease and liver cancer.  

Currently available antiviral treatments have limited efficacy and are threatened by treatment induced and naturally occurring drug resistance, which is of particular concern in the event of severe, life threatening infections.

The influenza nucleoside analog in development by Riboscience, RBS-3165, has the potential to be the most highly efficacious therapy for flu, with broad spectrum activity against all influenza strains, including pandemic (e.g. H1N1 “Swine Flu”) and emergent (e.g. “Bird Flu”) strains. 

In the US, RSV is the number one cause of pneumonia among infants less than 1 year old. RSV is also a significant cause of death among the elderly and the immunocompromised. There is no effective treatment for RSV.

The RSV nucleoside analog in development by Riboscience, RBS-3149, has the potential to be the most simple, safe and efficacious therapy for children and adults with RSV. 

According to the World Health Organization (WHO), neglected tropical diseases (NTD) affect more than 1 billion people worldwide.  Many of these NTD's are viral infections that could be cured or prevented using nucleoside analogs.  Dengue is now common in more than 100 countries with highest prevalence in the Americas, South-East Asia and Western Pacific regions.  Severe dengue (previously known as dengue hemorrhagic fever) has become a leading cause of hospitalization and death among children and adults in these regions.  

In partnership with Government agencies, Riboscience is developing nucleoside analogs for the treatment of Dengue, Ebola, Chikungunya and Zika virus.